Management of Chronic Hepatitis B Virus Infection: A Consensus Report of the Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases

Akhan, Sıla; Aynıoğlu, Aynur; Çağatay, Atahan; Gönen, İbak; Günal, Özgür; Kaynar, Teoman; Kuruüzüm, Ziya; Sayan, Murat; Tunca, Berivan; Tülek, Necla; Üçkardeş, Hüseyin; Yavuz, Ayşe Filiz; Yıldız, Orhan; Yılmaz, Neziha; Yüksel, Esma

doi:10.5152/kd.2014.26

Cited by 10 publications

(3 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Globally, LAM had been the only option for the treatment of CHB for a long time. With the launch of new treatments with high resistance barriers, LAM is mainly transformed into short-term use in patients receiving immunosuppressive treatment [8]. Until recently, the first treatment option for CHB patients was supposed to be LAM or telbivudine (LdT) if their HBV DNA level was <10 7 IU/mL, according to the Communique on Healthcare Practices (CHP) in Turkey.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of chronic hepatitis B patients receiving lamivudine: Single center experience

Yapar¹,

AKDOĞAN²

2022

Journal of Surgery and Medicine

View full text Add to dashboard Cite

Background/Aim: Lamivudine (LAM), which has been used for the treatment of Chronic Hepatitis (CHB) infection for many years, is now provided for short-time use to immunosuppressive patients due to resistance. We aimed to evaluate the current state and pandemic period routine follow-ups in patients who still used LAM today due to treatment or prophylaxis in terms of virologic or serologic treatment response. Methods: In this retrospective cohort study, we included 33 patients who received LAM treatment or prophylaxis due to CHB. Evaluations included patients' serologic results for Hepatitis B, platelet counts, comprehensive metabolic panel, HBV DNA levels, ultrasonographic (USG) evaluation of the liver, and the number and duration of outpatient visits between 01.01.2020 and 31.12.2021. Results: Of all the patients, 51.5% (n=17) were males, and the average age was 57.3 (12.3) years. The median LAM treatment duration was found 10 (2.58) years. The ratio of receiving LAM due to immunosuppressive therapy was 27.27% (n=9). Except for HBV DNA-negative patients or patients with no accessed results, the virologic response rate of patients was found 60.7% (n=20). Within the study period, while Anti-Hbe seroconversion was found 3.2% (n=1), Anti-Hbs seroconversion was found 6.5% (n=2). One patient whose virologic response was not obtained, received the treatment without any alterations in the regimens. While the number of outpatient follow-ups in the study period was found 1.94 (0.24) on average, the duration between follow-ups was found 13.82 (12.8) months. Conclusion:It is pleasing to obtain virologic response and Anti-HBs, Anti-HBe seroconversion in patients with low resistance profile who receive the LAM treatment. While watchful waiting is recommended for patients receiving long-term LAM treatment, our retrospective analysis showed that planned outpatient follow-ups for every three months was done in longer intervals. The treatment is not altered in one patient whose virologic response was not obtained because of inadequate number of follow-ups within the study period. Since monitoring without having prolonged follow-up durations due to the pandemic is of importance in terms of preventing complications, we believe that there is a need for further studies on this issue.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of chronic hepatitis B patients receiving lamivudine: Single center experience

Yapar¹,

AKDOĞAN²

2022

Journal of Surgery and Medicine

View full text Add to dashboard Cite

show abstract

“…Pegile interferon ile tedaviye yanıt hızlarının yüksek olmasına karşın, uzun süreli izlemde relaps oranlarının fazla olduğu saptanmıştır (8) . Deri altına enjeksiyon şeklinde uygulanması ve yan etkilerinin sık görülmesi dezavantajlarını oluşturmaktadır.…”

Section: Discussionunclassified

Investigation of Antiviral Drug Resistance in Patients Receiving Antiviral Therapy for Chronic Hepatitis B

Timur¹,

Ökahmetoğlu²,

Özüberk³

et al. 2017

TMCD

View full text Add to dashboard Cite

“…In the acute exacerbation and chronic periods, HBV and HCV diseases might lead to serious workforce loss, and mortal diseases, such as hepatocellular carcinoma, cirrhosis [2]. The economical burden associated with hepatitis diseases increases with treatment costs as well as workforce loss and early deaths.…”

Section: Introductionmentioning

confidence: 99%

Incidence of Hepatitis B and C Infections in Patients of Mental Disorders

Dönmezdil¹,

Yalçın²,

Temiz³

2017

Dicle Tıp Dergisi

View full text Add to dashboard Cite

Ojective: It is estimated that Hepatitis B (HBV) and Hepatitis C (HCV) diseases have high morbidity, affecting more than 400 million people in the world. Turkey is considered as a semi-pandemic region for these infections. Methods: In this study, our aim is to determine the seroprevalance of HBV and HCV in psychiatric hospitalized patients which is thought to be the risk group and to support the literature in terms of protective precautions in the progressed stages. Our study was performed between February-2014 and January 2015 in Diyarbakır Selahaddin Eyyubi State Hospital psychiatry clinic. The patient's files were investigated retrospectively, the results of serological tests (HBsAg, AntiHBS and AntiHCV) and socio-demographical data (age, sex, diagnoses and living areas) were used. Results: HBSAg positivity was 1.7% in schizophrenia patients, 0,8% in bipolar affective disorder patients, 0.4% in retarded patients and 0,3% in depression patients. A statistically significant relationship was found between schizophrenia and HBSAg. Conclusion: Similar precautions against viral hepatitis with high transmission rates should be applied in the chronic, disabled psychiatric patients just like the normal population. Active immunization will be useful in the schizophrenia group patients having relatively more risk. Extensive studies should be performed to obtain detailed and accurate data. Keyword 52 Incidence of Hepatitis B and C Infections in Patients of Mental Disorders ÖzetGiriş: Hepatit B (HBV) ve C (HCV) hastalıkları, dünyada 400 milyondan fazla kişiyi etkilediği tahmin edilen, yüksek morbiditeye sahip hastalıklardır. Bu enfeksiyonlar açısından Türkiye, yarı endemik bölge olarak gösterilmektedir. Yaptığımız bu çalışmada riskli grupta olduğu düşünülen yatarak tedavi gören psikiyatri hastalarındaki HBV ve HCV seroprevalansını belirlemek ve ileri dönemde hastalarımızda koruyucu amaçlı neler yapılabileceği hakkında literatüre katkıda bulunmaktır. Yöntemler: Çalışmamız Şubat-2014 ile Ocak 2015 tarihleri arasında Diyarbakı ili Selahaddin Eyyubi Devlet Hastanesi psikiyatri kliniğinde yatarak tedavi gören hastaların dosyalarının geriye doğru incelenerek serolojik testlerin sonuçları (HBsAg, AntiHBS ve AntiHCV) ve sosyodemografik verileri (yaş, cinsiyet, tanılar ve yaşam yerleri) kullanılarak yapılmıştır. Bulgular: Psikiyatrik tanılar ile hepatit serolojileri karşılaştırıldığında HBSAg pozitifliği şizofreni hastalarında %1,7, bipolar affektif bozukluk hastalarında %0,8, zeka geriliği olanlarda %0,4 ve depresyon hastalarında %0,3 olarak bulundu. Şizofreni ile HBSAg pozitifliği arasında istatistiksel olarak anlamlı bir ilişki tespit edildi. Sonuç: Kronik ve yeti yitimi ile seyreden psikiyatrik hastalıklarda bulaş riski yüksek viral hepatitler açısından toplumla benzer önlemler alınması, görece daha fazla risk barındıran şizofreni grubu hastalarda aktif bağışıklama yapılması faydalı olacaktır. Daha detaylı ve kesin verilere ulaşabilmek için geniş tabanlı çalışmalara ihtiyaç vardır.

show abstract

Management of Chronic Hepatitis B Virus Infection: A Consensus Report of the Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases

Cited by 10 publications

References 100 publications

Evaluation of chronic hepatitis B patients receiving lamivudine: Single center experience

Evaluation of chronic hepatitis B patients receiving lamivudine: Single center experience

Investigation of Antiviral Drug Resistance in Patients Receiving Antiviral Therapy for Chronic Hepatitis B

Incidence of Hepatitis B and C Infections in Patients of Mental Disorders

Contact Info

Product

Resources

About